Alpha Cancer Technologies Inc. (ACT) is a private clinical stage biotechnology company with platform technologies in Immunotherapy and Immuno-Oncology. These platforms under development treat auto-immune disease indications and cancer. The company’s drug products use our proprietary recombinant human alpha fetoprotein (AFP).
Bristol-Myers Squibb is a 14% equity shareholder with no other commercial rights.
Preclinical studies show ACT-903 demonstrates tumor suppression, increased survival, maytansine and metabolite accumulation in the tumor, and no signs of toxicity
Alpha Cancer Technologies Inc. (ACT) a biopharmaceutical company focused on developing and commercializing targeted immuno-oncology and immunology therapies based on its proprietary recombinant human Alpha Fetoprotein (AFP) platform, today announced the presentation of new preclinical data from the Company’s investigational therapy, ACT-903 at the European Society of Medical Oncology (ESMO) Annual Meeting being held virtually September 16-21, 2021.
View Full Press Release
View Poster
Alpha Cancer Technologies Inc. (ACT) a biopharmaceutical company focused on developing and commercializing targeted immuno-oncology and immunology therapies based on its proprietary recombinant human Alpha Fetoprotein platform, today announced that its abstract featuring data from the Company’s investigational therapy, ACT-903, has been selected for presentation at the European Society of Medical Oncology (ESMO) Annual Meeting being held virtually September 16-21, 2021.
Details about the abstract selected for poster publication can be found below:
https://thejeffreyfoundation.org/newsletter/jay-gatsby-character-analysis-essay/17/
https://ramapoforchildren.org/youth/persuasive-essay-organizer/47/
https://www.lapressclub.org/hypothesis/econometric-thesis/29/
mit 17 viagra generic
persuasive essay lesson plans high school
go here
enter site
https://chanelmovingforward.com/stories/help-me-write-my-thesis/51/
university essays for sale
bhavesh mishra essay definition
essay christmas day in english
https://chfn.org/fastered/levitra-udaipur-hotels/36/
essay writing case study
how would you solve this math problem
diflucan and
https://www.pugetsoundnavymuseum.org/paraphrasing/sample-research-paper-autism/24/
https://teamwomenmn.org/formatting/caliban-essay/23/
grant writing service
click here
frequency of taking viagra
https://smartfin.org/science/algo-natural-tipo-viagra/12/
prednisone vs medrol
go to site
116 b book by caroline cooney down essay flight
i want to buy benemid
sample resume writing format
source link
problem solving by systems
click
source site
buy generic viagra online in usa
Title: AFP-Maytansine Conjugate – a Novel Targeted Cancer Immunotherapy
Abstract Number: 523P
Authors: I. Sherman, R. Boohaker, K. Stinson, P. Griffin, W. Hill
Abstracts are under embargo until 5:00 p.m. ET on Sept. 15, 2021.
For more information about the Annual Meeting, please visit: https://www.esmo.org/meetings/esmo-congress-2021
AbSci, a growth-stage synthetic biology company whose Protein Printing™ technology enables rapid and low-cost biomanufacturing of difficult-to-produce biotherapeutics, today announced that it has entered into an agreement to license its E. coli SoluPro® protein expression technology to Alpha Cancer Technologies for the production of Recombinant Human Alpha-fetoprotein (hAFP). hAFP is a natural human protein produced by human embryo and yolk sac during development and can be used in the treatment of various autoimmune diseases and cancers. This license is an expansion of a previous collaboration between the parties that began last year.
Download
Alpha Cancer Technologies Inc. (ACT) a biopharmaceutical company focused on therapies for patients with autoimmune diseases and cancer, today announced the results of a study of ACT-101 (recombinant human alpha fetoprotein or rhAFP) in the treatment of Inflammatory Bowel Disease (IBD) at the World Congress of Gastroenterology 2017, held in partnership with The American College of Gastroenterology in Orlando, Florida. The study was sponsored by ACT to corroborate published clinical trial results using native human AFP.
Download
Alpha Cancer Technologies Inc. (ACT) a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with autoimmune diseases and cancer based on its proprietary recombinant human Alpha Fetoprotein today announced that the abstract describing the results of a pre-clinical study of the efficacy of ACT-101 in a mouse model of inflammatory bowel disease (IBD) has been submitted for presentation at the World Congress of Gastroenterology at ACG 2017 to be held in Orlando, Florida October 13-18, 2017.
Download
